882873--9/17/2010--UROLOGIX

related topics

{product, liability, claim}

{stock, price, share}

{stock, price, operating}

{cost, regulation, environmental}

{provision, law, control}

{property, intellectual, protect}

{personnel, key, retain}

{control, financial, internal}

{product, market, service}

{customer, product, revenue}

{acquisition, growth, future}

{regulation, government, change}

Third party reimbursement is critical to market acceptance of our products. We are faced with intense competition and rapid technological and industry change. We depend upon our Cooled ThermoTherapy products for all of our revenues. We have a history of unprofitability. We may need additional capital to continue our business, which may not be available in the amount or at the time we need it. We currently fail to meet one of NASDAQ s listing requirements and if our common stock is delisted it may then become illiquid. Government regulation has a significant impact on our business. We are dependent upon a limited number of third-party suppliers to manufacture our products. Our business of the manufacturing, marketing, and sale of medical devices involves the risk of liability claims and such claims could seriously harm our business, particularly if our insurance coverage is inadequate. We are dependent on adequate protection of our patent and proprietary rights. Our products may be subject to product recalls even after receiving FDA clearance or approval, which would harm our reputation and our business. We are dependent on key personnel. Fluctuations in our future operating results may negatively affect the market price of our common stock. Our stock price may be volatile and a shareholder s investment could decline in value. Future sales of shares of our common stock may negatively affect our stock price. Provisions of Minnesota law, our governing documents and other agreements may deter a change of control of us and have a possible negative effect on our stock price.

Full 10-K form ▸

882873--9/17/2010--UROLOGIX_INC